Verona Pharma Soars 9.3% on TD Cowen's Buy Rating

On April 29, 2025, Verona Pharma's stock surged by 9.3% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

TD Cowen initiated coverage of Verona Pharma with a Buy rating and a $100 price target. This move reflects the firm's optimism about the company's early momentum and potential for growth. The positive outlook from TD Cowen is likely to bolster investor confidence in Verona Pharma's future prospects.

Verona Pharma has been the subject of recent analyst recommendations, with TD Cowen's initiation of coverage being a notable development. The firm's Buy rating and $100 price target underscore the company's strong position in the market and its potential for further growth. This positive sentiment from a reputable analyst firm is expected to drive continued interest in Verona Pharma's stock.